Omnicell (NASDAQ:OMCL) versus Zhongchao (NASDAQ:ZCMD) Critical Survey

Zhongchao (NASDAQ:ZCMD) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zhongchao and Omnicell, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhongchao	1	0	0	0	1.00
Omnicell	1	1	6	0	2.63

Omnicell has a consensus price target of $58.50, indicating a potential upside of 78.63%. Given Omnicell’s stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Zhongchao.

Institutional & Insider Ownership

1.7% of Zhongchao shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 28.6% of Zhongchao shares are held by company insiders. Comparatively, 2.5% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Zhongchao has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Zhongchao and Omnicell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zhongchao	N/A	N/A	N/A
Omnicell	0.17%	3.00%	1.81%

Earnings and Valuation

This table compares Zhongchao and Omnicell”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhongchao	$15.86 million	0.44	-$640,000.00	N/A	N/A
Omnicell	$1.18 billion	1.26	$2.05 million	$0.04	818.75

Omnicell has higher revenue and earnings than Zhongchao.

Summary

Omnicell beats Zhongchao on 11 of the 12 factors compared between the two stocks.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.